A lack of association between the IKZF2 rs12619285 polymorphism and coronary heart disease

  • Authors:
    • Huadan Ye
    • Qingxiao Hong
    • Yirun Li
    • Xuting Xu
    • Yi Huang
    • Limin Xu
    • Annan Zhou
    • Youping Deng
    • Shiwei Duan
  • View Affiliations

  • Published online on: February 10, 2015     https://doi.org/10.3892/etm.2015.2282
  • Pages: 1309-1313
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The IKZF2 rs12619285 polymorphism is associated with the eosinophil count, which has multidimensional functions in the pathogenesis of coronary heart disease (CHD). The aim of the present study was to investigate the contribution of the IKZF2 rs12619285 polymorphism to the risk of CHD in a Han Chinese population. In total, 721 CHD cases and 631 non‑CHD controls were recruited for an association study of the IKZF2 rs12619285 polymorphism. Genotyping was performed using the melting temperature‑shift polymerase chain reaction method. No statistically significant association was observed between the IKZF2 rs12619285 polymorphism and CHD (odds ratio, 1.139, 95% confidence interval, 0.927‑1.334; P=0.17). In addition, subgroup analyses by gender or age were unable to identify any association between IKZF2 rs12619285 and CHD (P>0.05), and there was no significant correlation between IKZF2 rs12619285 and the severity of CHD (P>0.05). The power of the case‑control study was determined to be 63.3%. In addition, the G allele frequency was calculated as 63.6% in the Han Chinese population, which was similar to the 59.3% recorded for the HapMap Chinese population of Han Chinese individuals living in Beijing, compared with 24.3% in European descendents (HapMap‑CEU). Therefore, the results indicated that the IKZF2 rs12619285 polymorphism was not associated with CHD in a Han Chinese population. The discrepancy in the association between rs12619285 and CHD may be due to the ethnic differences between Han Chinese and European populations.

Introduction

Coronary heart disease (CHD) is a major cause of mortality and disability worldwide (1). The global number of CHD-induced mortalities is increasing rapidly and is hypothesized to reach 23.3 million by 2030 (2). CHD is induced by the accumulation of plaques on vascular endothelial surfaces (3,4). As a complex disease, CHD is influenced by lifestyle, environmental and genetic factors (1,5). Twin studies have provided evidence that genetic and environmental factors play key roles in the occurrence and development of CHD (68).

The IKZF2 gene is located on chromosome 2q13 and encodes the zinc-finger protein, Helios, which is a member of the Ikaros family of zinc-finger proteins. IKZF2 protein is a functional component in lymphocyte differentiation (9) and plays a key role in the growth of the early hematopoietic system (10). Hematopoietic progenitors can develop into neutrophils, eosinophils, dendritic cells, Langerhans cells, macrophages and osteoclasts (11). Infiltration of eosinophils has been found in the myocardial tissue of patients with hypereosinophilic syndrome (12). The rs12619285 polymorphism of the IKZF2 gene has been associated with a variation in the blood eosinophil count (13). Furthermore, genes that are involved in the regulation of eosinophil numbers have been shown to be involved in the inflammatory regulation and immune responses that occur during the development of CHD (1416). Eosinophils, as a type of white blood cell, exert multidimensional functions in the occurrence and development of autoimmune diseases (17), particularly in the pathogenesis of CHD (18,19) by promoting thrombus formation (20).

In addition, a previous study found that the IKZF2 rs12619285 (G/A) polymorphism in European populations (G allele frequency, 26%; P=5.4×10−10) and East Asian populations (G allele frequency, 64%; P=0.017) was significantly associated with CHD (21), although there were large allele differences between the European and East Asian populations. Previously, preliminary results indicated that there was an association between IKZF2 rs12619285 and CHD in the Chinese Han population [G allele frequency, 62.8%; P=0.07; odds ratio (OR), 1.38, 95% confidence interval (CI), 0.97–1.98], with no departure from the Hardy-Weinberg equilibrium (HWE) in the controls (22). Thus, an association was observed between IKZF2 rs12619285 and CHD (162 cases and 113 controls); however, the statistical power was only 45.2% (22). The small sample size used in this preliminary study may have been unable to indicate the authentic association between rs12619285 and CHD (22). Thus, the aim of the present study was to investigate the association between the rs12619285 polymorphism of the IKZF2 gene in CHD patients and non-CHD controls using an increased sample size.

Materials and methods

Sample collection

In total, 1,352 samples were collected between September 2011 and July 2013 in Ningbo Lihuili Hospital (Ningbo, China) and Ningbo Yinzhou People’s Hospital (Ningbo, China). CHD cases were confirmed with angiographic evidence that showed vascular stenosis of >50% in at least one major coronary artery. In addition, participants with a history of angioplasty or coronary artery bypass surgeries were classified as CHD cases. Control samples comprised patients whose vascular stenosis was <50% in each of the major coronary arteries (23). The severity of CHD was classified according to the number of major coronary arteries affected by >50% stenosis (single, double and triple). All the participants were unrelated and of Han Chinese origin, habituating in Zhejiang province. Patients were excluded from the study if they suffered from congenital heart disease, cancer and severe liver or kidney diseases. All the blood samples were collected by the same investigator. This study was approved by the Ethical Committees of Ningbo Lihuili Hospital and Ningbo Yinzhou People’s Hospital. All the individuals provided written informed consent.

Single nucleotide polymorphism genotyping

Genomic DNA from the peripheral blood was extracted using a nucleic acid automatic extractor (Lab-Aid 820; Zeesan Biotech Co., Ltd., Xiamen, China) and all the DNA samples were stored in Tris-EDTA buffer. Genotyping was performed using the melting temperature-shift polymerase chain reaction (PCR) method (24,25). The Tm-shift PCR approach was used to differentiate the two allele-specific PCR products that were amplified using two forward primers and one common reverse primer. The two forward primers comprised one long and one short primer to generate two PCR products with different Tm values. The primers used were as follows: IKZF2-g forward, 5′-GCGGGCAGGGCGGCA CCAAGGAAAATGGAGCTTCTG-3′; IKZF2-a forward, 5′-GATTACCGACCAAGGAAAATGGAGCTTCTA-3′); and IKZF2 reverse, 5′-GCCTCTTTAGGTAGGGAAGAG AGAACACA-3′. The PCR amplification program consisted of an initial denaturation at 95°C for 30 sec, followed by denaturation at 95°C for 30 sec, annealing at 59°C for 30 sec and extension at 72°C for 30 sec for 40 cycles, and a final extension at 72°C for 30 sec. PCR was performed using the ABI GeneAmp® PCR System 9700 with the 96-Well Sample Block Module (Applied Biosystems Life Technologies, Foster City, CA, USA). Subsequently, melting curve analysis was performed using a Roche LightCycler 480® fluorescence quantitative PCR instrument (Roche Diagnostics, Basel, Switzerland). The melting curve analysis program was 95°C for 15 sec, 60°C for 30 sec, followed by increasing the temperature by 0.11°C per sec, until a temperature of 95°C was reached. As shown in Fig. 1, the data of the melting curve analysis was obtained by clustering the fluorescence intensity analysis (25).

Statistical analysis

HWE analysis was performed using Arlequin software (version 3.5; Zoological Institute, University of Bern, Bern, Switzerland) (26). Differences in the genotype and allele frequencies between the case and control groups were calculated using CLUMP 22 software (Institute of Psychiatry, Denmark Hill, London, UK) with 10,000 Monte Carlo simulations (27). OR and 95% CI values were determined using an online program (http://faculty.vassar.edu/lowry/odds2x2.html). The Cochran-Mantel-Haenszel (CMH) test was performed using SAS 9.2 software (SAS Institute, Marlow, UK), while power analysis was conducted using the software of Power and Sample Size Calculation (version 3.0.43; Department of Biostatistics, Vanderbilt University, Nashville, TN, USA) (28). A two-tailed P-value of <0.05 was considered to indicate a statistically significant difference.

Results

Distribution of genotypes and alleles in the case and control groups

In total, 721 CHD cases and 631 controls were recruited for the study in order to evaluate the contribution of the IKZF2 rs12619285 polymorphism to CHD. Genotype distributions of the IKZF2 rs12619285 polymorphism were shown to not deviate from the HWE in the CHD cases, non-CHD controls and additional subgroups divided by gender or age (P>0.05; Tables I, II and III). The results did not reveal a statistically significant association between the rs12619285 polymorphism and CHD in the case-control study (P=0.17; OR, 1.139, 95% CI, 0.972–1.334; Table I).

Table I

Distribution of genotypes and alleles in the case and control subjects.

Table I

Distribution of genotypes and alleles in the case and control subjects.

GenotypeControls (n=631)Single vessel (n=352)Double vessels (n=168)Triple vessels (n=201)Total cases (n=721)χ2P-value (df=2)P-value (df=1)OR (95% CI)
AA8445111773
AG29115679101336
GG25615178833123.5460.170.1091.139 (0.972–1.334)

[i] OR, odds ratio; CI, confidence interval; df, degree of freedom.

Table II

Distribution of genotypes and alleles according to gender.

Table II

Distribution of genotypes and alleles according to gender.

GenderGenotype (n)χ2P-value (df=2)HWEAllele (n)χ2P-value (df=1)OR (95% CI)


GGAGAAGA
Male
 Cases (n=516)217242570.441676356
 Controls (n=345)140157481.5880.4520.7304372530.8520.3561.099 (0.899–1.344)
Female
 Cases (n=205)9594160.326284126
 Controls (n=286)116134363.5340.1710.8983662062.9780.0841.269 (0.968–1.663)

[i] OR, odds ratio; CI, confidence interval; df, degree of freedom; HWE, Hardy-Weinberg equilibrium.

Table III

Distribution of genotypes and alleles according to age.

Table III

Distribution of genotypes and alleles according to age.

Genotype (n)Allele (n)


Age (years)GGAGAAχ2P-value (df=2)HWEGAχ2P-value (df=1)OR (95% CI)
≤55
 Cases (n=166)7079170.494219113
 Controls (n=224)87108290.8620.6500.6672821660.7560.3851.141 (0.848–1.536)
55–65
 Cases (n=244)99113321.000311177
 Controls (n=243)95113350.2150.8980.8923031830.2000.6551.061 (0.818–1.377)
≥65
 Cases (n=311)143144240.148430192
 Controls (n=164)7470202.6540.2650.6012181100.7050.4011.130 (0.849–1.503)

[i] OR, odds ratio; CI, confidence interval; df, degree of freedom; HWE, Hardy-Weinberg equilibrium.

Associations with age and gender

Since the development of CHD may be involved with the interaction between genovariation and the environment (29), the samples were divided into subgroups according to age and gender (30,31), from which subgroup association tests were performed. Subgroup analysis by gender did not identify an association between the rs12619285 polymorphism and CHD in males (P=0.356; OR, 1.099, 95% CI, 0.899–1.344; Table II) or females (P=0.084; OR, 1.269, 95% CI, 0.968–1.663). In addition, an association was not identified between rs12619285 and CHD in the breakdown analysis by age (P>0.05; Table III).

Associations with genetic models and the severity of CHD

Association tests were also performed using dominant and recessive genetic models. However, no statistically significant difference in the distribution of rs12619285 genotypes or alleles were identified between the case and control subjects (P>0.05; Table IV). In addition, CMH statistical analysis was performed to investigate the association between rs12619285 and the number of arteries with stenosis in the CHD patients. Similarly, no statistically significant association was identified between the rs12619285 polymorphism and the severity of CHD (P>0.05; data not shown). In addition, the G allele frequency was found to be 63.6% in the Han Chinese population, which was similar to the previous preliminary study where the G allele frequency was 62.8% (22). The power of the present case-control study was 63.3%.

Table IV

Genotyping under dominant and recessive models.

Table IV

Genotyping under dominant and recessive models.

rs12619285Dominant (GG/AG+AA)χ2P-value (df=1)OR (95% CI)Recessive (GG+AG/AA)χ2P-value (df=1)OR (95% CI)
Total cases312/409648/73
Total controls256/3751.0090.3151.117 (0.900–1.388)547/843.3300.0681.363 (0.977–1.903)
Male cases217/299459/57
Male controls140/2050.1850.6671.063 (0.806–1.402)297/481.5870.2081.301 (0.863–1.963)
Female cases95/110189/16
Female controls116/1701.6290.2021.266 (0.881–1.818)250/362.8840.0901.701 (0.916–3.157)

[i] OR, odds ratio; CI, confidence interval; df, degree of freedom.

Discussion

In the present case-control study, a statistically significant association between IKZF2 rs12619285 and CHD was not identified, although there was a borderline statistical difference between the CHD cases and non-CHD controls in the female subgroup (P=0.08). The case-control study included 1,352 individuals that comprised 721 CHD cases and 631 controls. However, the current study was relatively small compared with a previous genome-wide association study that included 12,118 European and 5,212 East Asian individuals (21). Insufficient sample size may explain the negative association observed in the present study (statistical power, 63.3%).

Further analysis indicated that there was an ethnic difference in the allele frequency of the IKZF2 rs12619285 polymorphism. The G allele frequency of rs12619285 in the HapMap European population was found to be 24.3%, which was much smaller compared with that of the HapMap Han Chinese in Beijing (CHB) population (59.3%). In addition, the G allele frequency was 63.6% in the controls of the present study, which was similar to that of the HapMap-CHB (59.3%) population (32). The discrepancy in the allele frequency may help to explain why the present study failed to confirm the previously identified positive association between the IKZF2 rs12619285 polymorphism and CHD in the Han Chinese population.

Genetic heterogeneity may be an additional explanation for the negative results. A total of 3,355 polymorphisms have been identified in the IKZF2 gene. The current study only focused on one polymorphism of the IKZF2 gene; thus, the function of the IKZF2 gene may not be fully demonstrated. Future studies should investigate a greater number of polymorphisms in order to improve the understanding of the role of the IKZF2 gene in the susceptibility of CHD.

IKZF2 protein has been identified at an early phase of development in thymocytes; thus, IKZF2 has been regarded as a key regulator in lymphocyte differentiation (9). In addition, IKZF2 has been demonstrated to be involved in the earliest hematopoietic differentiation of human embryonic stem cells (33), and neutrophils and eosinophils are developed from hematopoietic progenitors (11). Eosinophils participate in the production and reproduction of inflammation (21), which may promote the development of CHD (34,35). Thus, it was hypothesized that the IKZF2 gene may play a role in the pathogenesis of CHD.

In conclusion, the present case-control study demonstrated a lack of association between the IKZF2 rs12619285 polymorphism and CHD in the Han Chinese population. This observation indicated that other IKZF2 polymorphisms or different genes can affect the variation in blood eosinophil numbers, which may further the understanding into the contribution of inflammatory pathways in CHD.

Acknowledgements

The study was supported by grants from the National Natural Science Foundation of China (nos. 31100919 and 81371469), the Natural Science Foundation of Zhejiang Province (no. LR13H020003), the K.C. Wong Magna Fund in Ningbo University and the Ningbo Social Development Research Projects (no. 2012C50032).

References

1 

Lopez AD, Mathers CD, Ezzati M, Jamison DT and Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 367:1747–1757. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e4422006. View Article : Google Scholar : PubMed/NCBI

3 

Libby P: Inflammation in atherosclerosis. Nature. 420:868–874. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Kroupis C, Theodorou M, Chaidaroglou A, et al: The association between a common FCGR2A polymorphism and C-reactive protein and coronary artery disease revisited. Genet Test Mol Biomarkers. 14:839–846. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Samani NJ, Erdmann J, Hall AS, et al; WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med. 357:443–453. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Mangino M and Spector T: Understanding coronary artery disease using twin studies. Heart. 99:373–375. 2013. View Article : Google Scholar

7 

Dai J, Krasnow RE, Liu L, Sawada SG and Reed T: The association between postload plasma glucose levels and 38-year mortality risk of coronary heart disease: the prospective NHLBI Twin Study. PLoS One. 8:e693322013. View Article : Google Scholar : PubMed/NCBI

8 

Vaccarino V, Goldberg J, Rooks C, et al: Post-traumatic stress disorder and incidence of coronary heart disease: a twin study. J Am Coll Cardiol. 62:970–978. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Georgopoulos K, Winandy S and Avitahl N: The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol. 15:155–176. 1997. View Article : Google Scholar : PubMed/NCBI

10 

Kelley CM, Ikeda T, Koipally J, et al: Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. Curr Biol: CB. 8:508–515. 1998. View Article : Google Scholar : PubMed/NCBI

11 

Chio KD, Vodyanik M and Slukvin II: Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc. 6:296–313. 2011. View Article : Google Scholar

12 

Engelmann MG, Kolbe T, Faul C and Steinbeck G: Hypereosinophilic syndrome associated with heterozygous factor V gene mutation: an unusual combination resulting in an acute coronary syndrome and recurrent cerebral stroke - a case report. Angiology. 55:221–225. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Buysschaert ID, Grulois V, Eloy P, et al: Genetic evidence for a role of IL33 in nasal polyposis. Allergy. 65:616–622. 2010. View Article : Google Scholar

14 

Akhabir L and Sandford A: Genetics of interleukin 1 receptor-like 1 in immune and inflammatory diseases. Curr Genomics. 11:591–606. 2010. View Article : Google Scholar

15 

Sekkach Y, Mekouar F, Jira M, et al: Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy. Ann Pharm Fr. 69:277–281. 2011.(In French). View Article : Google Scholar : PubMed/NCBI

16 

Singh RK, Gupta S, Dastidar S and Ray A: Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 85:336–349. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Hogan SP, Rosenberg HF, Moqbel R, et al: Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 38:709–750. 2008. View Article : Google Scholar : PubMed/NCBI

18 

Roivainen M, Viik-Kajander M, Palosuo T, et al: Infections, inflammation, and the risk of coronary heart disease. Circulation. 101:252–257. 2000. View Article : Google Scholar : PubMed/NCBI

19 

Sato Y, Fukunaga T, Hayashi T and Asada Y: Hypereosinophilic syndrome associated with occlusive coronary thrombosis and right ventricular thrombus. Pathol Int. 58:138–141. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Sakai T, Inoue S, Matsuyama TA, et al: Eosinophils may be involved in thrombus growth in acute coronary syndrome. Int Heart J. 50:267–277. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Gudbjartsson DF, Bjornsdottir US, Halapi E, et al: Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. 41:342–347. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Lian J, Huang Y, Huang RS, et al: Meta-analyses of four eosinophil related gene variants in coronary heart disease. J Thromb Thrombolysis. 36:394–401. 2013. View Article : Google Scholar : PubMed/NCBI

23 

No authors listed. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 59:607–609. 1979. View Article : Google Scholar : PubMed/NCBI

24 

Wang J, Chuang K, Ahluwalia M, et al: High-throughput SNP genotyping by single-tube PCR with Tm-shift primers. Biotechniques. 39:885–893. 2005. View Article : Google Scholar : PubMed/NCBI

25 

Yuan F, Xu J, Ji LD, et al: Application of Tm-shift genotyping method in genetic studies. Yi Chuan. 34:1484–1490. 2012.(In Chinese). View Article : Google Scholar : PubMed/NCBI

26 

Excoffier L and Lischer HE: Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 10:564–567. 2010. View Article : Google Scholar

27 

Sham PC and Curtis D: Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet. 59:97–105. 1995. View Article : Google Scholar : PubMed/NCBI

28 

Dupont WD and Plummer WD Jr: Power and sample size calculations. A review and computer program. Control Clin Trials. 11:116–128. 1990. View Article : Google Scholar : PubMed/NCBI

29 

Liu H, Huang XQ, Yang M, et al: MRAS genetic variation is associated with atherothrombotic stroke in the Han Chinese population. J Clin Neurol. 9:223–230. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Li X, He M, Zhu J, Yao P, Li X, Yuan J, Min X, Lang M, Yang H, Hu FB, Wu T and Wei S: Higher carbohydrate antigen 125 levels are associated with increased risk of coronary heart disease in elderly chinese: a population-based case-control study. PLoS One. 8:e813282013. View Article : Google Scholar : PubMed/NCBI

31 

Jiang D, Zheng D, Wang L, et al: Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PLoS One. 8:e597522013. View Article : Google Scholar : PubMed/NCBI

32 

National Center for Biotechnology Information. HapMap population allele frequency data. http://www.ncbi.nlm.nih.govuri. Accessed February 7, 2014

33 

Halsell SR and Kiehart DP: Second-site noncomplementation identifies genomic regions required for Drosophila nonmuscle myosin function during morphogenesis. Genetics. 148:1845–1863. 1998.PubMed/NCBI

34 

Jia LX, Qi GM, Liu O, Li TT, Yang M, Cui W, Zhang WM, Qi YF and Du J: Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. Cardiovasc Drugs Ther. 27:521–530. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Paoletti R, Gotto AM Jr and Hajjar DP: Inflammation in atherosclerosis and implications for therapy. Circulation. 109(23 Suppl 1): III20–III26. 2004. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April-2015
Volume 9 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ye H, Hong Q, Li Y, Xu X, Huang Y, Xu L, Zhou A, Deng Y and Duan S: A lack of association between the IKZF2 rs12619285 polymorphism and coronary heart disease. Exp Ther Med 9: 1309-1313, 2015.
APA
Ye, H., Hong, Q., Li, Y., Xu, X., Huang, Y., Xu, L. ... Duan, S. (2015). A lack of association between the IKZF2 rs12619285 polymorphism and coronary heart disease. Experimental and Therapeutic Medicine, 9, 1309-1313. https://doi.org/10.3892/etm.2015.2282
MLA
Ye, H., Hong, Q., Li, Y., Xu, X., Huang, Y., Xu, L., Zhou, A., Deng, Y., Duan, S."A lack of association between the IKZF2 rs12619285 polymorphism and coronary heart disease". Experimental and Therapeutic Medicine 9.4 (2015): 1309-1313.
Chicago
Ye, H., Hong, Q., Li, Y., Xu, X., Huang, Y., Xu, L., Zhou, A., Deng, Y., Duan, S."A lack of association between the IKZF2 rs12619285 polymorphism and coronary heart disease". Experimental and Therapeutic Medicine 9, no. 4 (2015): 1309-1313. https://doi.org/10.3892/etm.2015.2282